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ABSTRACT 
Therapeutic enzymes are proteins which can be used to treat rare and deadly diseases. They represent a small but profitable market. Therapeutic 
enzymes are superior to non-enzymatic drugs owing to their high specificity toward the target and also their ability to multiple substrate 
conversion. They are essential for speeding up all the metabolic processes and many a life-supporting chemical inter-conversions. Actinomycetes 
including Arthrobacter form an enormous reservoir of secondary metabolites and enzymes. The characterization of L-asparaginase, β-glucosidase, 
urate oxidase, methionine γ-lyase, acetyl cholinesterase, and arginase activities from actinomycetes Arthrobacter clearly demonstrate the potential 
of Arthrobacter as potent producer of therapeutic enzymes. These metabolic enzymes can be used either separately or in combination with other 
therapies for the treatment of several diseases such as leukemia, gout, asthma, and neurological disorders. The objective of this review is to compile 
the information on the application of therapeutic enzymes produced by Arthrobacter and their future prospects as drugs.  
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Among new drug substances, the use of proteins as pharma-
ceuticals is steadily increasing [1]. Microbes contribute to the production 
of the majority of commercially important bioactive compounds. The 
microorganisms have proved to be very efficient and economical source 
of therapeutic enzyme and are preferred over plants and animals, owing 
to their economic cultivation, stability, flexibility in process modification 
and optimization. All these characteristics facilitate the large-scale 
microbial production of enzymes [2]. Actinomycetes are widely 
distributed in the earth’s ecosystem and are the most potent resource of 
biotechnological and pharmaceutical studies [3]. Previous studies 
conducted on actinomycetes were directed mainly on antibiotic 
production, only a few reports citing the potential of actinomycetes for 
the production of enzymes have been listed. 
Microbial isolates belonging to genus Arthrobacter are a notable 
source for the production of therapeutic enzymes. The Arthrobacter 
genus constituted by Conn and Dimmick [4] consisting of more than 
84 species exhibiting high G+C content ranging from 59 to 66 mol% 
[5]. The species of Arthrobacter genus are most prevalent amongst 
soil bacteria. The member species of genus Arthrobacter are Gram-
positive and obligate aerobes. They form a soft and smooth colony 
which is yellow to white in coloration [6, 7]. They undergo rod-
coccus growth cycle. However, some members of the genus are 
spherical in shape, occurring in pairs and tetrad similar to A. agilis 
[4]. A. atrocyaneus, A. citreus and A. simplex exhibit mobility initially, 
but become non-motile after attaining coccoid morphology [8]. The 
Arthrobacter genus is metabolically versatile producing many 
different enzymes and also resilient to undesirable environmental 
conditions. They are prolific sources of medically important 
enzymes with multifarious applications. They are also used in the 
bioremediation of groundwater contaminated with pesticides and 
herbicides [9]. Arthrobacter sp. genera serve as bioindicators of 
contaminated habitats and also act as agents for bioremediation of 
contaminants, mostly by facilitating the synthesis of proteins for 
cellular survival [10].  
The application of microbial enzymes as the drug is an important 
aspect of the present-day pharmaceutical industry. A very high 
degree of purity is needed for therapeutic enzyme preparations. 
Usually, enzymes with low Km and high Vmax value are selected 
because of their maximal efficiency even at a very low concentration 
of enzyme and substrate. Thus, the selection of sources for the 
production of such enzymes is crucial [2]. A number of medically 
useful enzymes have been reported from genus Arthrobacter. 
Subsequently, isolates of Arthrobacter genus gained much attention 
of researchers. Taking into consideration the importance of 
therapeutic enzymes, the enzymes produced by the members of the 
genus Arthrobacter can be classified into three categories. These are 
pharmaceutical enzymes where the protein directly acts as the 
therapeutic agent, prodrug-activating enzymes where the protein 
indirectly results in a clinical effect and diagnostic enzymes where 
the protein is highly selective and specific to target and provide 
merit over available analytical methods (fig. 1). The information on 
the application of medically important enzymes produced by the 
members of the genus Arthrobacter is compiled in this review to 
explore the future prospects of these therapeutic enzymes as drugs.  
 
 
Fig. 1: Schematic illustration of different therapeutic enzymes 
reported from Arthrobacter sp 
 
Therapeutic enzymes producing Arthrobacter sp. of terrestrial 
origin 
Soil represents a promising habitat for discovering and isolating 
new natural products, and only<1% of soil bacterial species are 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491               Vol 10, Issue 11, 2018 
Azmi et al. 
Int J Pharm Pharm Sci, Vol 10, Issue 11, 1-5 
2 
currently known [11]. The Arthrobacter genus is an indigenous flora 
of soil and usually consists of an important section of the 
rhizosphere microflora. A key characteristic of Arthrobacter is their 
nutritional versatility with simple nutritional needs together with 
the ability to exploit a number of compounds as a source of carbon 
and nitrogen. The main features of Arthrobacter held responsible for 
their prominent ecological presence in arid soils are the minimum 
growth rate, the rapid decrease in endogenous metabolism, the 
accumulation of a considerable amount of reserve material, the high 
resistance to desiccation in soil, the small spheroidal shape of cells 
and the long survival times during starvation [12]. 
Cold-active β-galactosidase producing Arthrobacter sp. SB has been 
reported from Antarctic soil samples. This enzyme has an optimal 
growth temperature of 15-20 °C at pH 7.0 and a subunit molecular mass 
of 114 kDa. It is specific for lactose and not inhibited by calcium or 
sodium ions present in milk [13]. All these properties render it useful for 
the production of low-lactose milk for lactose intolerant people and can 
also be used as a supplement along with amylase, lipase, and protease in 
lactose intolerant people. Other species, namely A. psychrolactophilus F2, 
Arthrobacter sp. 32cB, Arthrobacter sp. 20B and Arthrobacter sp. ON14 
were also reported for production of cold-active β-galactosidase [14]. 
Arthrobacter sp. SD5 isolated from oil containing soil samples with lipase 
activity possess pharmaceutical applications. They studied medium 
composition and culture conditions for improved production of lipase. 
Olive oil (2.5%) as a carbon source, peptone (1.0 %) as a nitrogen source 
and Tween-80 (0.2%) as biosurfactant gave the optimal lipase yield [15]. 
Arthrobacter sp. strain PF01 obtained from Penguin feathers collected 
from Elephant Island, Antartica was found to produce keratinase with 
potential medical use [16]. Isolated a bacterium from ornithogenic soil 
and feather fragments with keratinolytic activity in low temperature 
(5°C). Arthrobacter sp. strain PF1 was identified based on morphological 
and biochemical tests and 16S rRNA sequencing. e bacterium 
presented optimum growth at 4 and 25 °C, but not at 37 °C. Proteolytic 
activity was observed at 4 and 25 °C in pH 7 an 
Therapeutic enzyme producing Arthrobacter sp. of aquatic origin 
Over billions of years, the ocean has been regarded as the origin of 
life on the Earth. Thereby marine microbial enzymes can offer novel 
biocatalyst with extraordinary properties. The best marine source of 
bacteria is sediment and also reported from water, sand, rocks, 
marine plants, mangrove sediment, and deep sediment. The 
psychrotrophic bacterium Arthrobacter sp. 32c isolated from 
Antarctic Ocean reported to produce cold-adapted β-D-
galactosidase. The enzyme is active at 4-8 °C and of molecular 
weight of 195 kDa and 75.9 kDa for native protein and monomer 
subunit respectively [17]. The lactose intolerance person is not able 
to metabolise lactose due to a congenital deficiency of the enzyme β-
galactosidase [18]. The β-galactosidase enzyme can be used to treat 
lactose intolerance. The bacterium A. oxydans producing dextranase 
was isolated from sea mud samples. This dextranase was reported 
for removal of dental plague and to treat dental caries [19]. 
An Arthrobacter sp. strain MAT3885 efficiently degrading chondroitin 
sulfate was isolated from marine environments. The optimum activity 
of chondroitin sulphate lyase was at pH 5.5-7.5 and 40 °C, with 10 min 
of reaction time. The native enzyme was found to be a monomer [20]. 
It has been exposed analytically that chondroitin lyases inhibit 
melanoma invasion, proliferation, angiogenesis and to treat 
invertebral disc protrusion. It fosters the reclamation of axons of the 
central nervous system after injury [21]. The bacterium A. ilicis 
isolated from the marine sponge Spirastrella sp. produces extracellular 
serine-type acetylcholinesterase. The maximum activity of acetyl 
cholinesterase was found at pH 8.0 and 45 °C [22]. Arthrobacter sp. 
strain TAD20, a chitinolytic organism, was isolated from the sea 
bottom along the Antarctic ice shell. The bacterium secretes two major 
chitinases, ChiA and ChiB in response to chitin induction [23]. These 
chitinases exhibit medical functions like elicitor action and anti-tumor 
activity and to treat human diseases like asthma [24].  
Production of enzymes with biomedical applications by 
Arthrobacter 
The major therapeutic enzymes produced by Arthrobacter along 
with their applications have been presented in table 1. 
L-asparaginase an important therapeutic enzyme belongs to 
amidase group. It accounts for about 40% of the global total enzyme 
sale. It is engrossed for the treatment of childhood acute 
lymphoblastic leukemia [25]. Its antileukemic effect work on the fact 
that tumor cells are incapable of synthesizing L-asparagine due to 
lack of aspartate-ammonia ligase activity. Administration of 
asparaginase depletes free exogenous L-asparagine thus left tumor 
cells in a state of fatal starvation [2]. 
Urate oxidase is an effective curative agent in gout treatment and 
act as a therapeutic drug to regulate uric acid levels. Urate oxidase 
was also used as a reagent to monitor uric acid levels in body fluids 
[26]. ElitekTM is commercially available intravenous dosage form of 
urate oxidase, which not only resolves the deposition of newly 
synthesized urate but also eliminates the long-standing tissue 
deposits [27, 28].  
β-glucosidase obtained from A. chlorophenolicus catalyzes efficient 
biotransformation of major ginsenosides to highly active minor 
ginsenosides like F2, Rh1,F1, etc. These minor ginsenosides show 
highly significant pharmacological activities including anti-fatigue, 
anti-inflammation, anti-neoplastic, anti-fatigue, anti-oxidant and 
anti-diabetic effects. The enzymatic transformation on these 
compounds is advantageous as it results in fewer byproducts, better 
environmental protection and higher stereo-specificity [29].  
Methionine γ-lyase (MGL) is used as a drug target for contagious 
ailments evoked by parasitic protozoa and anaerobic periodontal 
bacteria. Recombinant MGL also administered to cause a decline in 
the concentration of methionine essential for the growth of cancer 
cells. MGL degrades sulphur containing amino acids to α-keto acids, 
ammonia and volatile thiols [30].  
Acetylcholinesterase is mainly found at neuromuscular junctions 
where it serves to terminate synaptic transmission by hydrolyzing 
acetylcholine to inactive components namely choline and acetic acid. 
It is necessary for the conduction of impulses along the nerve and 
muscle fibers. It is used as a vaccine against Dictyocaulus viviparous 
and as a pretreatment drug in organophosphorus poisoning [22]. It 
is considered to be an important neurotransmitter in the regulation 
of cognitive function [31]. This enzyme regulates the acetylcholine 
levels, an anti-inflammatory molecule associated with the 
inflammatory response during parasitic diseases [32].  
Chondroitin lyase obtained from Arthrobacter sp. MAT3885 is 
effective in enhancing the regeneration of the central nervous 
system after injury and also help in improving keloid pathology. It is 
a chondroitin sulfate degrading enzyme results in production of 
chondroitin sulfate oligo or disaccharides which have a broad 
biological activity like in symptomatic treatment of osteoarthritis, 
known for its anti-inflammatory action, anti-oxidant activity and 
potent 2, 2-diphenyl-1-picrylhydrazyl (DPPH) scavenging activity 
[20]. 
Dextranase is known to prevent dental caries and repress dental 
plague. Dextranase obtained from Arthrobacter sp. strain B7 
hydrolyzed dextran and glucan from the dental plague. Dextranase 
works efficiently at temperatures of about 37 °C and are widely used 
in medical and dental industries. It is used in oral care products like 
toothpaste and mouthwash for effective dental caries prevention. It 
is also used in the manufacturing of blood substitutes [33, 34, 35].  
Arginase obtained from Arthrobacter sp. KUJ 8602 catalyses the 
hydrolysis of L-arginine. It involves in nutritional starvation therapy 
for treatment of human hepatocellular carcinoma, prostate cancer, 
and melanoma. In addition to anticancer activity, it was proved to be 
effective in the treatment of acute neurological disorders, 
rheumatoid arthritis and allergic asthma [36].  
Inulase II Arthrobacter sp. H65-7 produces the enzyme inulase 
II that converts inulin into difructose anhydride (DFA). DFA is a 
promising nutrient for fighting osteoporosis because it helps 
absorption of calcium in the intestines [37, 38]. 
Hyaluronate lyase was obtained by cultivating A. globiformis strain 
A152. The optimum pH and temperature values for hyaluronate 
lyase activity were pH 6.0 and 42 °C, respectively [39]. It has been 
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successfully utilized in ophthalmic surgery and dermatosurgery. It 
has been applied as a local adjuvant to expand the diffusion capacity 
of local anesthetics, thus enhancing the analgesic efficacy and the 
anesthetized area, especially in the first few minutes following 
injection, mitigating intra and postoperative pain [40]. 
Cyclodextrin glycosyltransferase (CGTase) was obtained from A. 
mysorens isolated from paddy field soil. CGTase catalyzes cyclisation 
of α-1, 4-glucans to produce cyclodextrins. Cyclodextrins are carrier 
molecules useful in pharmaceuticals for preparation of immediate 
release oral dosage forms. The molecular weight of the purified 
protein as determined by SDS-PAGE was 75kDa; purified CGTase 
was thermostable and stable over a wide pH range. Dissolution 
studies on β-cyclodextrin-Irbesartan complex revealed that β-CDs 
form was useful in preparing immediate release oral dosage forms of 
the drug [41]. 
 
Table 1: Major therapeutic enzymes produced by Arthrobacter 
S. No. Enzymes  Microorganisms Applications Reference 
1 Acetylcholinesterase A. ilicis Used as a pretreatment drug in organophosphorus poisoning and as 
a vaccine against Dictyocaulus viviparous 
22 
2 Amine transaminase Arthrobacter sp. KNK168 Synthesis of sitagliptin and medicine for type-2 diabetes 42 
3 Arginase Arthrobacter sp. KUJ 
8602 
Anticancer activity 36 
4 Chitinase Arthrobacter sp. Antifungal agent 43 
5 Cholesterol oxidase A. simplex U-S 3011 Diagnosis of arteriosclerosis and determination of serum cholesterol  44 
6 Chondroitin lyase Arthrobacter sp. 
MAT3885 
Effective against keloid pathology and in the regeneration of central 
nervous system after injury  
20 
7 Creatinase A. nicotianae 23710  Application in clinical diagnosis of renal function 45 
8 Cyclodextrin 
glycosyltransferase 
A. mysorens Production of β-cyclodextrin useful in preparing immediate release 
oral dosage forms 
41 
9 Deaminase A. oxydans Used in anticancer and antibacterial therapies 46 
10 Dehydrogenase A. simplex 156 Steroid drug biotransformation 47 
11 Dextranase Arthrobacter sp.  Dental caries-preventing agent 34 
12 D-threonine aldolase Arthrobacter sp. DK-38 Production of bioactive molecules 48 
13 Ethanolamine oxidase Arthrobacter sp. Detection of phosphatidylethanolamine levels in serum  49 
14 Fibrinolytic enzyme FA-I A. aurescens strain DR-
536 
Used as a thrombolysis agent 50 
15 Hyaluronate lyase  A. globiformis A152 Used in ophthalmic surgery and dermatosurgery 39, 40 
16 Keratinase Arthrobacter sp. strain 
PF01 
Transmissible spongiform encephalopathies treatment 16, 51 
17 L-arabinose isomerase Arthrobacter sp. Produce D-tagatose which acts as a drug for anti-diabetic and 
obesity control 
52 
18 L-asparaginase A. kerguelensis VL-
RK_09 
Antileukemic effect 25 
19 Levanfructo-transferase A. ureafaciens K2032 Production of DFA IV, which act as a low-calorie sweetener, inhibit 
tooth decay, increase mineral absorption 
53 
20 Lipase Arthrobacter sp. MTCC 
5125 
Resolution of chiral drugs and their intermediates 54 





Block quorum sensing 55 
23 Oxidoreductases Arthrobacter sp. Production of enantiomerically pure alcohols 56 
24 Penicillin acylase A. viscosus ATCC15294 Production of semisynthetic penicillins 57 
25 Protease A. luteus Potential target for developing therapeutic agents against fatal 




Arthrobacter sp. Produce L-serine which is used to treat hereditary sensory, 
autonomic neuropathy type 1 
60, 61 
26 Tyramine oxidase Arthrobacter sp B-
0813  
Diagnosis of Leucine aminopeptidase activity in serum 62 
27 Urate oxidase A. globiformis FERM 
BP-360 
Gout treatment and detection of uric acid in serum 63 
28 Xanthine oxidase Arthrobacter sp. Used in amperometric biosensors for detection of xanthine and 
hypoxanthine 
64 
29 β-1, 3-glucanase Recombinant A. luteus Paratransgenic control of Chagas disease 65 
30 β-galactosidase A. psychrolactophilus Production of low lactose milk for treatment of hypolactasia 66 
31 β-glucosidase A. chlorophenolicus Produce active minor ginsenosides having anti-neoplastic, anti-




The member species of Arthrobacter genus have evolved as a group 
with vast metabolic and genomic diversity. Attempts should be aimed 
to explore the potential of Arthrobacter sp. as a source to produce 
novel therapeutic enzymes. The results of research on the use of 
Arthrobacter group for the production of therapeutic enzymes 
targeting various diseases have been presented. Although, symbolic 
progress in the discovery of different medically important enzymes 
has been conducted, but their large-scale commercial production is yet 
to be worked out. Purification is the primary step in the processing of 
therapeutic enzymes. Successful reports on medically important 
enzymes from terrestrial and aquatic Arthrobacter are available, but 
their commercial production conditions are yet to be investigated. In 
order to generate therapeutic enzymes as commercial products, 
different biosynthetic pathways need to be analyzed, then respective 
genes should be metabolically engineered, cloned into the desired host 
and bioprocess parameters have to be optimized. 
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